HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

Marianne Tuefferd, Jérôme Couturier, Frédérique Penault-Llorca et al. · 2007

Read HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients by Marianne Tuefferd, Jérôme Couturier, Frédérique Penault-Llorca et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001138.txt.

Description

Ovarian cancer often responds well to first chemotherapy, then returns in a drug-resistant form. Marianne Tuefferd and a multicenter French group, GINECO, examined a possible drug target in a 2007 PLOS ONE article. The target is HER2, a growth signal protein already used to guide treatment in breast cancer.

The study measured HER2 status in ovarian cancers from 320 patients. Targeted drugs such as trastuzumab exist for HER2-driven tumors, so knowing how often ovarian cancers carry the marker matters for trial design. The paper gives a large, multi-center count of how common HER2 positivity is in this disease.

Catalog record

CREATORMarianne Tuefferd, Jérôme Couturier, Frédérique Penault-Llorca et al.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001138

Browse the full library · About the Tower of Babel